Individual hypersensitivity to the active substance or to any of the supporting components of the preparation.
Children under 18 years of age, pregnant and breast-feeding (clinical experience with the drug in children, women during pregnancy and breastfeeding is not).
Use of the drug proviron 25mg during pregnancy is contraindicated, as clinical experience with its use during pregnancy is not available.
Reproduction studies in animals did not reveal any differences between insulin degludek and human insulin in terms of embryotoxicity and teratogenicity.
Use in breast-feeding period is contraindicated, since clinical experience of its use in lactating women is not available.
Animal studies have shown that in the rat insulin degludek excreted in breast milk, the drug concentration in breast milk is lower than in blood plasma.
It is unknown whether insulin degludek excreted in breast milk of women.
In animal studies found no adverse effects of insulin degludek fertility.
Dosing and Administration
The dproviron 25mg is an insulin analog extremely long action.
The drug is administered subcutaneously 1 time per day at any time of day, but it is preferable to introduce the drug in the same time each day.
In patients with type 2 diabetes can used both as a monotherapy and in combination with oral agents or bolus insulin (see. Subpart Pharmacodynamics) .
Patients with type 1 diabetes prescribers in combination with insulin short / rapid-acting, to cover mealtime insulin requirements . The dose should be determined individually according to the patient’s needs. Recommended correction dose based on indicators of blood plasma glucose to optimize glycemic control on an empty stomach.
As with all insulin preparations, dosage adjustment may also be needed in strengthening the patient’s physical activity, changing its usual diet or during concomitant illness .
Patients with type 2 diabetes mellitus
The recommended initial daily dose of the drug proviron 25mg is 10 units, followed by the selection of an individual dose.
Patients with type 1 diabetes administered once a day in combination with prandial insulin that is administered with a meal, followed by the selection of an individual dose.
Transfer from other insulin preparations
recommended careful monitoring of blood glucose concentration during the transfer and in the first weeks of the appointment of a new drug. You may need correction of concomitant hypoglycemic therapy (dose and timing of administration of insulin preparations and a short-acting oral agent or dose).